Possibility to use direct oral anticoagulants to prevent thromboembolic events in patients with COVID-19

Abstract

Hospitalized patients with COVID-19 who have not previously received DOAK by it is not advisable to prescribe POAC for the prevention of thrombosis in patients with COVID-19 due to the lack of clinical trial results, significant potential interactions.

Keywords

• коронавирус
• прямые пероральные антикоагулянты
• covid-19